Skip to main content

Table 1 Tissue samples and amounts of immunopurified HLA class I

From: Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation

Tissue

specimen

Tumor (T)

Normal renal

tissue (NK)

Metastasis (M)

Type

Mass

(g)

TILs

Edman

results

(pmol)

Average

HLA

amount

(pmol/g)

RCC399

NK

T

M (lymph node)

ccRCC

2.4

13.8

1.0

yes

60

1000

40

25.0

72.5

40.0

RCC377

NK

T

M (lymph node)

ccRCC

4.2

12.7

4.5

n.d

500

6000

3500

119.0

472.4

777.8

RCC364

NK

T

M (lymph node)

ccRCC

1.2

5.8

0.4

yes

10

1000

20

8.3

172.4

50.0

Rcc343

NK

T

M (liver)

ccRCC

3.2

2.1

3.2

n.d

20

200

1400

6.3

95.2

437.5

RCC70

NK

T

M (lymph node)

ccRCC

4.4

8.3

2.6

n.d.

300

3200

200

68.2

385.5

76.9

RCC307

NK

T

pRCC

2.7

1.6

n.d.

200

400

74.1

250.0

RCC211

NK

T

pRCC

0.4

20.7

n.d.

10

2100

25.0

101.4

RCC193

NK

T

ccRCC

2.4

4.7

n.d.

500

850

208.3

180.9

RCC131

NK

T

ccRCC

6.5

11.5

n.d.

400

300

61.5

26.1

RCC121

NK

T

ccRCC

6.2

10.4

no

500

460

44.2

80.6

RCC119

NK

T

ccRCC

8.9

7.8

yes

440

560

49.4

71.8

RCC110

NK

T

chRCC

13.0

7.0

yes

1700

3900

130.8

557.1

RCC100

NK

T

ccRCC

12.6

8.0

no

1400

1200

111.1

150.0

RCC99

NK T

ccRCC

12.4

7.7

no

1500

1300

121.0

168.8

RCC81

NK

T

chRCC

10.0

18.0

no

1400

1800

100.0

140.0

RCC76

NK

T

ccRCC

6.2

12.8

n.d.

1200

2600

193.5

20.3

RCC71

NK

T

ccRCC

9.0

7.0

n.d.

10

3000

1.1

428.6

RCC58

NK

T

ccRCC

7.6

7.2

no

2000

2400

263.2

333.3

RCC57

NK

T

n.d.

6.8

8.7

yes

1900

2500

279.4

287.4

RCC53

NK

T

n.d.

6.9

6.2

n.d.

1300

1900

188.4

306.5

RCC52

NK

T

ccRCC

7.4

7.0

n.d.

100

2000

13.5

285.7

RCC51

NK

T

chRCC

7.0

7.8

n.d.

2100

2000

300.0

256.4

RCC49

NK

T

n.d.

7.0

8.8

n.d.

1300

2900

185.7

329.5

RCC46

NK

T

n.d.

7.6

9.3

n.d.

400

1500

52.6

161.3

RCC173

NK

M (contralateral k.)

ccRCC

5,0

5,1

n.d.

40

240

8.0

47.1

RCC249

T

chRCC

2.6

n.d.

80

30.8

RCC231

T

pRCC

6.3

n.d.

380

60.3

RCC226

T

ccRCC

6.8

n.d.

250

36.8

RCC195

T

ccRCC

60.0

n.d.

50

0.8

RCC130

T

ccRCC

6.0

no

1100

183.3

RCC125

T

ccRCC

15.5, 8.1

n.d.

400

25.8

RCC116

T

ccRCC

15.8

yes

2380

150.6

RCC115

T

ccRCC

26.0

yes

12900

496.2

RCC113

T

ccRCC

10.1

n.d.

200

19.8

RCC108

T

pRCC

30.0

yes

1500

50.0

RCC103

T

chRCC

10.0

yes

4400

440.0

RCC101

T

ccRCC

7.5

yes

800

106.7

RCC98

T

ccRCC

21.1

n.d.

2100

99.5

RCC90

T

ccRCC

20.0

n.d.

10200

510.0

RCC75

T

pRCC

16.0

n.d.

2200

137.5

RCC73

T

ccRCC

10.0

n.d.

1300

130.0

RCC68

T

ccRCC

20.0

yes

2500

125.0

RCC395

M (lymph node)

ccRCC

1.4

n.d.

50

35.7

RCC333

M (pancreas)

ccRCC

10.9

yes

3000

275.2

RCC328

M (contralateral k.)

ccRCC

1.5

n.d.

300

200.0

RCC112

M (adrenal gland)

ccRCC

2.5

n.d.

700

280.0

RCC126

NK

ccRCC

8.9

yes

200

22.5

  1. Total and normalized HLA yields of all tissue samples analyzed in this study. Weight, histological subtype and information about present TILs are indicated for each examined RCC (tumor, normal tissue and metastases). HLA typing was carried out by the Institute for Clinical and Experimental Transfusion Medicine and histologic classification was performed by the Department of Pathology, University of Tübingen, Germany. T, tumor; NK, normal kidney; M, metastasis; n.d., not determined; ccRCC, clear cell renal cell carcinoma; pRCC, papillary renal call carcinoma; chRCC, chromophilic renal cell carcinoma; no, no TILs detected; yes, TILs detected.